Healthcare
OmniAb, Inc.(OABIW)
Live Price
Offline$0.107
+18.89% today
1Y Change
-63.10%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $160.00M
- Revenue Growth
- -29.3%
- EPS Growth
- +6.6%
- Dividend Yield
- 0.0%
Coverage: 125 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OmniAb, Inc. (OABIW) is a Healthcare stock with a market cap of $160.00M and listed on NASDAQ. The stock last traded around $0.11 and down 63.1% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -29.3%, EPS growth of +6.6%, a dividend yield of 0.0%. What stands out right now is revenue -29.3%, EPS +6.6%, free cash flow +10.9% with operating margin -383.1% and ROIC -24.8%. Valuation already assumes a fairly strong business story at price/sales 8.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OABIW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-29.3% vs +7.6% peer median
Operating Margin
Below sector median
-383.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -29.3% and EPS is at +6.6%, with operating margin around -383.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 4, 2026 | -25.0% | +0.0% | +0.3% | +0.3% |
2025 Nov 4, 2025 | -4.6% | +12.8% | -26.3% | -37.8% |
Benchmark Edge
OABIW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OABIW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OABIW Max Drawdown
-74.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OABIW and SPY.
Company Overview
OmniAb, Inc.
NASDAQ Capital Market
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
- Leadership
- Matthew W. Foehr
- IPO Date
- Sep 30, 2021
- Employees
- 114
- Street Address
- 5980 Horton Street
- Mailing
- EmeryVille, CA, 94608
- Region
- EmeryVille, CA, US
- Reporting Currency
- USD
- Investor Line
- 510 250 7800
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.5
- Price/Book
- 0.7
Growth
- Revenue
- -29.3%
- EPS
- +6.6%
- Free Cash Flow
- +10.9%
Profitability
- Gross Margin
- 73.5%
- Operating Margin
- -383.1%
- Net Margin
- -347.0%
- ROE
- -24.0%
- ROIC
- -24.8%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 4.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.